Detection of p53 exon 9 gene mutation in bladder cancer by polymerase chain reaction-single-strand conformation polymorphism method

Abstract

Introduction: Urinary bladder cancer is the fourth most common diagnosed malignancy in men and the tenth in women worldwide. The successful treatment depends on early detection and specific diagnostic approaches. Mutations in the p53 tumor suppressor gene (TP53) are very common among the cancers, especially in bladder cancer that p53 mutation is identified in around 60 percents. Aims: In this study, we aim to detect p53 mutation in bladder cancer patients in Kermanshah city of Iran. Materials and Methods: Thirty paraffin-embedded specimens were obtained from bladder cancer patients. They were reviewed by pathologists for substantial amounts of neoplastic tissue. PCR-SSCP technique was used followed by standard silver staining to analyze TP53 exon 9 gene mutations in tumor samples. RESULTS: Polyacrylamide gel analysis represented mutations in 2 cases (6.7%) that were classified as p53-positive, and there were no mutations in 28 cases (93.3%) that were classified as p53-negative. No significant correlation observed between p53 mutation and histological grade, tumor stage, muscular propria status, patient sex, and age. Conclusion: These data are the first report on the p53 abnormalities in bladder cancer patients from Kermanshah. We can suppose that the percentage of p53 exon 9 mutation is low in bladder cancer patients from western Iran. However, further studies on a large number of tissue specimens, if possible, help to verify the obtained results.

Detection of R282w P53 Gene Mutation on Exon 8 in Gastric Cancer Patients in Southwest Iran

“…The Saffari-Chaleshtori and colleagues study found no mutation in exon8 of the P53 gene in gastric patients Shahrekord city (42). Abbasi and colleagues reported a mutation rate of 6.7% in p53 in the bladder of patients with cancer in Kermanshah city (western are of Iran) (43). Lohrasbi Nejad and colleagues found 4 mutations at the P53 gene (codons: 140, 142, 184 and 248) in colorectal cancer patients in Kerman province (40).…”

Oncology Gold Standard™ consensus statement on counseling patients for molecular testing and personalized cancer care

“…They are called variations of unknown significance. [4,10,11,25,26] So if this testing is done in 100 patients with adenocarcinoma of lung, 55% will show a known mutation and <45% will remain with unknown genetic alterations [ Figure 2]. The Figure 2: Standard pathological classification versus driver mutation classification in lung cancer 55% with known mutations will include 35% who will have actionable driver mutations.…”

“…This insight has the potential to facilitate the selection of the best treatment option for patients with specific mutations. [4,10,11,25,26] We now know that the chance (incidence) and type of mutations have geographical variations of importance. For instance, the EGFR mutations are seen in a tiny fraction of patients in the western world, whereas its incidence is higher in patients from India and surrounding countries.…”

“…This enables us to decide which testing is necessary and how to interpret its results specific for our patients. [4,11,12,[23][24][25][26]…”

Label-Free and Amplified Electrochemical Detection of Single Nucleotide Polymorphism in Folded Nucleic Acid Secondary Structures

“…Traditional and classical SNP detection methods include single strand conformation polymorphism analysis (SSCP), 12 restriction fragment length polymorphism analysis, 13 and capillary electrophoresis. 14 In recent years, some automated methods have also been developed, such as DNA chip detection, 15,16 DNA sequencing, 17 and denaturing high performance liquid chromatography.…”